Clerkenwell Health, founded last year with ambitions to help make the UK a world leader in psychedelics research, is outfitting a clinic near Harley Street, central London, that will be Europe’s first commercial setting for clinical trials. The first trial, scheduled to start at the end of this year, will involve treating 60 people with terminal cancer who all have adjustment disorder — which means they are struggling to come to terms with their diagnosis — with a combination of psilocybin and psychotherapy.